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Background. We have previously described the presentation of epidermodysplasia verruciformis (EV)–like
eruptions in almost a quarter of hospitalized adolescents with vertically-acquired human immunodeficiency virus
(HIV) infection in Harare, Zimbabwe, a region with a high prevalence of HIV infection.
Methods. We performed a clinical case note review and skin biopsy from affected sites in 4 HIV-infected
adolescents with EV-like lesions in Harare. Biopsies were processed for histology and for human papillomavirus
(HPV) typing.
Results. All patients had long-standing skin lesions that pre-dated the diagnosis of HIV by several years. The
histology of skin biopsies from all patients was consistent with EV. In each biopsy, EV-associated b-HPV type 5
was identified (additionally, type 19 was found in 1 biopsy). Cutaneous wart–associated HPV types 1 and 2 were
detected in all biopsies, together with genital lesion–associated HPV types 6, 16, and 52, (as well as$3 other genital
lesion–associated HPV types). Despite immune reconstitution with combination antiretroviral therapy (cART),
there was no improvement in EV-like lesions in any patient.
Conclusions. EV is a disfiguring and potentially stigmatizing condition among this patient group and is difficult
to treat; cART appears to have no impact on the progression of skin disease. Among adolescents with longstanding
HIV-induced immunosuppression and with high levels of sun exposure, close dermatological surveillance for
potential skin malignancy is required.
Classical epidermodysplasia verruciformis (EV) is a hu-
man papillomavirus (HPV)–related condition, manifest
as widespread, persistent, banal macules or papules
resembling common flat warts or pityriasis versicolor.
It starts on the hands and forehead in childhood [1],
spreading to involve other sun-exposed sites. With
time, lesions may become more prominent and ver-
rucous, and may progress to invasive squamous cell
carcinoma.
The disease results from a genetic susceptibility to
chronic disseminated infection with HPV of the ß
papillomavirus group. Evidence suggests a genetic
heterogeneity of the disease rather than X-linked or
autosomal-dominant inheritance. Homozygous mu-
tations in either the EVER1 and EVER2 gene located
on chromosome 17 have been frequently identified
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[2, 3]. Although classically an autosomal-recessive condition,
acquired EV has been reported in immunodeficiency states,
including sporadic reports in adults with human immunode-
ficiency virus (HIV) infection [4–10].
We have previously described the presentation of EV-like
eruptions, commonly termed planar warts, in up to a quarter
of hospitalized adolescents with vertically acquired HIV in-
fection in Harare, Zimbabwe [11]. Here, we report the his-
tological findings and results of HPV typing performed on
skin biopsies taken from affected sites in 4 HIV-infected
adolescents in Harare.
CASE REPORTS
Patient 1 was diagnosed with HIV infection in 2005 at 13 years
of age. Since the age of 8, he had complained of a persistent,
nonitchy skin rash covering his face and arms. There was
no family history of skin disease and no other past medical
history of note. A physical examination revealed widespread
flat, nonscaly, hypopigmented macules from 1 to 15 mm.
The lesions were distributed on the sun-exposed areas of
his upper torso, face, neck, and forearms. The genital area,
other mucous membranes, scalp, and nails were unaffected.
Koebnerization was frequent. A clinical diagnosis of planar
warts was made. No specific treatment was available. In July
2005, he commenced combination antiretroviral therapy
(cART) with nevirapine, lamivudine, and stavudine. His nadir
CD4 T-cell count was 193 cells/lL (8% of the total lym-
phocyte count). After starting cART, his CD4 T-cell count
improved to 964 cells/lL (25% of the total lymphocyte count)
in 2008 and he remained clinically well. However, the cuta-
neous eruption had not improved (Figure 1A).
Patient 2 was found to be infected with HIV in 2005, at the
age of 12. Since 2001 at age 8, he complained of a persistent
nonitchy hypopigmented rash covering sun-exposed areas,
including the legs, but with no genital lesions. There was no
family history of skin disease. He commenced cART in March
of 2007. The nadir CD4 T-cell count at that time was 186 cells/lL
(11% of the total lymphocyte count). Sixteen months later, he
was clinically well and his CD4 T-cell count had improved to
479 cells/lL (23%). The skin eruption remained unchanged
despite the introduction of cART (Figure 1B).
Patient 3 was diagnosed with HIV infection in 2007 at the
age of 15. Since the age of 7, he had complained of a persistent
maculopapular eruption similar in distribution and morphology
to patients 1 and 2. He commenced cART in December of 2007
with a nadir CD4 T-cell count of 180 cells/lL. In 2011, his CD4
T-cell count was 414 cells/lL and his skin manifestations re-
mained unchanged (Figure 1C).
Patient 4 was found to be infected with HIV in 2002 when he
was 13 years old, following a diagnosis of pulmonary tuber-
culosis. At that time, disseminated flat warts were noted
Figure 1. A–D, Physical examination of all 4 cases revealed multiple hypopigmented papules distributed on the trunk, neck, face, and upper limbs.
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involving the face and limbs with scattered truncal lesions;
these had been present for several years. He commenced cART
in 2006, but the nadir CD4 T-cell count was not recorded. In
2010, his CD4 T-cell count was 97 cells/lL and the skin rash
remained unchanged (Figure 1D).
All 4 patients were vertically infected with HIV: all were
maternal orphans, denied previous sexual intercourse, and
reported no blood transfusions or intravenous drug use.
MATERIALS AND METHODS
Tissue Samples
Diagnostic punch skin biopsies were taken from each patient
with informed consent (Table 1). The samples were split: one
half was processed for light microscopy and the other half was
fixed in formalin for transport, and then rinsed in phosphate
buffered saline at 4C before homogenization. Tissue was
digested with a 200 lg/mL solution of proteinase K overnight
at 37C, and DNA was extracted using phenol/chloroform and
ethanol precipitation.
HPV Typing
Two comprehensive HPV typing systems were utilized in 2
separate specialist HPV research laboratories that could identify
cutaneous wart–associated HPV types, b (EV-associated) types,
and genital HPV types. First, polymerase chain reaction (PCR)
was performed, followed by sequencing using primers that
amplify a wide spectrum of HPV types; PGMY, GP51/GP61,
CP65/CP70, CP66/CP70, and CH1F/CN1R [12, 13]. Next,
confirmatory HPV typing was done using a Luminex-based
system (cutaneous HPV) and 2 reverse hybridization line probe
assays (LiPA) (genital and b-HPV) [14–16]. The final HPV
typing outcome was obtained by combining the results of all
the methods used. HPV viral load assays were available for
common b and genital HPV types (HPV 5 and HPV 6, 11, 16,
and 18, respectively) [17].
RESULTS
Histopathology
The histological findings in each patient’s biopsy included
basket-weave orthokeratosis overlying a prominent granular
cell layer. Acanthosis, mild spongiosis, focal lymphocyte
Table 1. Human Papillomavirus Types Isolated
Patient
Site of
Skin Biopsy
HPV Types HPV Type Summary
b/EV
Types
Cutaneous
Wart–Associated
Types Genital Types
HPV Types With Highest
Signal Intensities (Quantitative
and Semiquantitative Data)
1 Neck 5 1, 2 6, 16, 18, 45, 52, 53, 54 HPV 1 111
HPV 2 11
HPV 61
2 Shoulder 5,19 1, 2 6, 11, 16, 18, 31, 33, 52 HPV 1111
HPV 211
3 Arm 5 1, 2 6, 11, 16, 31, 51, 52, 66 HPV 1111
HPV 211
4 Neck 5 1, 2 6, 11, 16, 18, 31, 52, 53, 66 HPV 1111
HPV 211
HPV 61
Abbreviations: EV, epidermodysplasia verruciformis; HPV, human papillomavirus.
Figure 2. Punch biopsy of skin showing an acanthotic epidermis
containing numerous koilocytes. The features are those of a plane wart,
which is a classic histological feature of epidermodysplasia verruciformis.
Hematoxylin and eosin stain, 100x original magnification.
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exocytosis, koilocytes, and occasional prickle layer keratinocytes
with enlarged nuclei were also observed. These histological
appearances are those of a plane wart as is typically seen in
epidermodysplasia verruciformis (Figure 2).
HPV Typing
HPV 5, a b-type (EV-associated) HPV, was detected in all biopsy
samples by LiPA, but very low copy numbers were detected by
real-time quantitative PCR. HPV 19, another b-HPV, was iso-
lated in sample 2. Multiple cutaneous wart–associated and
genital HPV types were also isolated from each sample (Table 1).
HPV types 1 and 2, usually found in plantar warts, were isolated
in all samples with both PCR/sequencing and Luminex tech-
niques; all samples had high HPV 1 signals. A large number of
genital HPV types were identified (7 or 8 in each sample).
HPV viral load testing was available for HPV 6, 11, 16, and 18.
However, only HPV 6 was found in levels above the detectable
limit in samples from patients 1 and 3; the copy number was
too low to permit accurate quantification.
DISCUSSION
We describe acquired EV in 4 adolescents with longstanding,
untreated vertically acquired HIV infection. Histology and HPV
typing are consistent with EV. In addition to identifying
‘‘expected’’ EV-associated b-HPV types in skin biopsies from
affected areas, HPV types 1 and 2 were detected in each bi-
opsy, as well as 7 or more HPV types normally associated with
genital lesions. Despite immune reconstitution with cART,
there was no improvement in the EV lesions, from which
multiple HPV strains were isolated after several years of oth-
erwise successful treatment. HPV 1 and 2, classically associated
with plantar warts, were also isolated in skin biopsies from our
patients, together with HPV 5, commonly found in patients
with congenital EV [18]. HPV 3, a cutaneous wart–associated
HPV type, has previously been identified in EV lesions from 1
HIV-infected individual; by contrast, HPV 1 or 2 have not been
described [9].
HPV infection is frequent in immunocompromised patients,
but there are few reports of EV occurring in acquired immu-
nodeficiency states [4–10]. Prior to this study, only 18 cases of
HIV-associated EV have been reported, and only 2 described
congenital HIV and EV [10, 19]. One of these 2 patients was
found to be homozygous for the C912A T polymorphism in the
TMC8/EVER2 gene [19].
More than 100 HPV types are recognised and classified into
3 clinical categories: anogenital or mucosal, cutaneous wart–
associated, and b-HPV types. b-HPV viruses are ubiquitous and
nonpathogenic in the normal population [20].
Classical EV results from a cell-mediated immune deficiency
and an accompanying underlying genetic susceptibility to
EV-HPV. This results in an inhibition of natural cytotoxic
mechanisms against HPV-infected keratinocytes, leading to
the development of skin lesions. Thus, is it possible that these 4
long-term survivors had an undefined, underlying genetic
susceptibility, but it is more likely that they had a long-standing,
acquired cell-mediated immune defect secondary to a chronic,
untreated HIV infection.
These vertically HIV-infected adolescents probably first
experienced HPV infection in early childhood when their cell-
mediated immune systems were already impaired by HIV,
whereas adults who are infected with HIV later in life have
robust immune mechanisms against HPV infection that were
developed in childhood when their immune systems were still
intact. This might explain why EV is not as common in HIV-
infected adults as it is in older HIV-infected children. Close
contact between these immunosuppressed children and other
HPV-infected children in an HIV clinic or with HIV-infected
adults with multiple HPV types is a possible explanation for
the unusually high number of genital and nongenital HPV
types isolated in each skin biopsy. Laboratory contamination
is an unlikely explanation for the detection of HPV types 19,
45, 51, 52, 53, 54, and 66, as these types were not stored in the
2 research laboratories.
There is no definitive treatment for EV. Lee et al [10] reviewed
the treatment of twenty patients with congenital EV and con-
cluded that oral retinoids (with or without interferon) were
effective, as was low-dose oral retinoid maintenance. Relapses
were common upon treatment cessation and caution is advised
when prescribing retinoids to adolescents with child-bearing
potential due to the recognized teratogenicity [10]. Topical
imiquimod, intralesional interferon, 5-fluorouracil, and ci-
metidine have all been used as treatment, but with variable
success [1, 6, 8, 10]. Previous reports suggest that treatment of
HIV-associated EV is less successful than that for classical EV.
Haas et al [7] report the resolution of lesions upon starting
cART in 1 adult patient. A recent treatment trial of glycolic acid
in HIV-positive children in Botswana showed a trend toward
flattening and color normalization in flat warts, although
complete resolution was observed in only 10% of patients.
Response was greatest in those developing warts after starting
ART and those with fewer HPV types [21]. In this resource-
limited setting, alternative treatments were not available and
immune reconstitution with cART had no impact on the
appearance of the lesions. This group of adolescents was left
with a disfiguring and potentially stigmatizing condition in high-
prevalence communities where the skin condition is frequently
identified as being associated with HIV infection.
Classical EV is associated with a high risk of lesional trans-
formation to squamous cell carcinoma, occurring in up to 70%
of cases [1, 22]. Malignant lesions usually occur in the third and
fourth decades of life, but there are case reports of carcinoma
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appearing as early as 15 and 17 years of age [1]. The oncogenic
potential of HPV 5 and 8 is well established but other EV-HPV,
including HPV 10, 14, 20, and 47, have also been implicated
[18, 22]. Both ultraviolet B and diagnostic X-ray radiation have
been identified as oncogenic cofactors in HPV 5–related malig-
nancies [1, 22]. Earlier malignant transformation in skin lesions
exposed to sunlight and radiotherapy has been reported [1]. No
malignancies were encountered in our series or other reported
cases of HIV-associated EV, but as cART becomes more widely
available, adolescents surviving to adulthood will need close
dermatological surveillance. This is particularly important
among this group of children with longstanding immune
deficiency and high levels of sun exposure.
In summary, we describe 4 HIV-infected adolescents with EV-
like lesions. Preliminary results suggest that among long-term
survivors of vertically-acquired HIV, this might be a common
clinical HPV phenotype. It is a disfiguring condition and diffi-
cult to treat because no impact on the progression of skin
disease has been observed after the administration of cART.
EV is relatively rare in HIV-infected adults but appears to be
frequent in vertically-infected children, and close dermato-
logical surveillance for potential skin malignancy is required.
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